Nature Immunology 6, 1182 - 1190 (2005)
Published online: 17 November 2005; | doi:10.1038/ni1275
Immune cell migration in inflammation: present and future therapeutic targetsAndrew D Luster1, Ronen Alon2
& Ulrich H von Andrian31
Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. 2
Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel. 3
The CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA.
Correspondence should be addressed to Andrew D Luster luster.andrew@mgh.harvard.edu or Ronen Alon ronen.alon@weizmann.ac.il or Ulrich H von Andrian uva@cbr.med.harvard.edu The burgeoning field of leukocyte trafficking has created new and exciting opportunities in the clinic. Trafficking signals are being defined that finely control the movement of distinct subsets of immune cells into and out of specific tissues. Because the accumulation of leukocytes in tissues contributes to a wide variety of diseases, these 'molecular codes' have provided new targets for inhibiting tissue-specific inflammation, which have been confirmed in the clinic. However, immune cell migration is also critically important for the delivery of protective immune responses to tissues. Thus, the challenge for the future will be to identify the trafficking molecules that will most specifically inhibit the key subsets of cells that drive disease processes without affecting the migration and function of leukocytes required for protective immunity.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
